FridayOct 27, 2023 12:19 pm

Stanford Study Finds Lung Cancer Cells Hide, Thrive in the Brain

Researchers from Stanford Medicine have found that lung cancer cells can spread to the brain and hide from the immune system by pretending to be “baby neurons.” After originating in the lungs, these cancer cells can metastasize into the brain and avoid detection by convincing neural cells that they’re juvenile neurons through the secretion of a certain chemical signal. These cancer cells secrete a chemical message/signal that is ubiquitous during times of brain development, which attracts brain cells called astrocytes to the cells. This chemical signal encourages the astrocytes to secrete other chemical signals that protect the lung cancer cells…

Continue Reading

FridayOct 27, 2023 9:45 am

PaxMedica Inc.’s (NASDAQ: PXMD) CEO and Corporate Communications Chief Discuss Regulatory Strategy for Lead Drug Candidate and Future Plans in Recent Bell2Bell Podcast Interview

PaxMedica Chairman and CEO Howard Weisman participated in a recent Bell2Bell Podcast interview and was joined by Buzz Woods from Corporate Communications Weisman discussed the company’s strategy to seek FDA approval for Suramin as a treatment for Human African Trypanosomiasis (“HAT”) and plans for 2024 If PaxMedica is successful in getting approval in HAT, the company believes that could lead to the receipt of a Priority Review Voucher (“PRV”) The company hopes to monetize the PRV to raise funds that will support research and future trials investigating Suramin as a treatment for Autism Spectrum Disorder PaxMedica hopes to file an…

Continue Reading

FridayOct 27, 2023 9:00 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Showcase Its Boutique End-to-End CDMO Services at the Premier CPHI Barcelona Event

Scinai will exhibit at the upcoming CPHI Barcelona event, showcasing its CDMO services The company expanded into the CDMO business earlier this year, operating under the banner Scinai Bioservices Scinai’s boutique end-to-end CDMO business division serves pharmaceutical, biotech, and alternative protein food tech companies with pilot and clinical process development and cGMP manufacturing Scinai intends to serve small biotech companies who require CDMO services with superior value compared to large, multinational CDMO companies Scinai will also exhibit at the upcoming BIO-Europe conference in Munich Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products,…

Continue Reading

ThursdayOct 26, 2023 2:51 pm

Biotech Firms Register Successes in Quest for Better Pancreatic Cancer Treatments

The American Cancer Society’s Cancer Facts & Figures 2023 report revealed a 1% increase in five-year survival rates for pancreatic cancer, which increased from 11% to 12%. Released in early 2023, the report represented the first instance since 2017 that five-year survival rates for pancreatic cancer increased for two years in a row. It indicates that we are making slow but steady progress against pancreatic cancer, a hard-to-treat cancer that originates in the pancreas before spreading to other organs and tissues. In many cases, pancreatic cancer spreads to the lungs, abdominal walls, lymph nodes and bones, resulting in symptoms such…

Continue Reading

WednesdayOct 25, 2023 12:13 pm

Four Marketing Channels that eCommerce Firms Can Leverage

In an incredibly competitive market such as e-commerce, where 90% of companies fail, marketing is key to standing out from the competition and maintaining profitability. The right marketing channel mix can help you drive traffic to your merchant sites, increase conversions and boost your virtual store’s revenue. Although billions of people buy and sell online every year, attracting and retaining customers to a platform can be incredibly difficult. Traditional marketing techniques may not translate well to e-commerce. Even with the right techniques, you may not have much marketing success if you don’t devise a proper mix of marketing channels. Search…

Continue Reading

WednesdayOct 25, 2023 9:00 am

Clene Inc. (NASDAQ: CLNN) Announces Four-Year Grant to Support Expanded Access Protocol for CNM-Au8 From NINDS

Clene's wholly-owned subsidiary, Clene Nanomedicine Inc., in collaboration with Columbia University and Synapticure, has been awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (“NINDS”) The study will monitor safety, survival, clinical worsening, and key disease progression-related biomarkers while using CNM-Au8 Research conducted by Clene estimates that ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the US and an estimated 500,000 people worldwide, with a life expectancy of diagnosed patients typically ranging from three to five years Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company on…

Continue Reading

TuesdayOct 24, 2023 9:37 am

Spanish Clinical Trial to Explore Marijuana as Glioblastoma Treatment

A major marijuana company has announced that it will begin supplying cannabis to a Spanish clinical trial investigating marijuana’s potential as a glioblastoma treatment. Tilray Brands subsidiary Tilray Medical will sponsor an upcoming clinical study to test whether marijuana can treat glioblastoma, one of the hardest-to-treat types of brain cancer. The study will be conducted by Complutense University of Madrid and Spanish Neuro-Oncology Research Group (GEINO) scientists at Madrid’s University Hospital. For the research, researchers will recruit 30 recently diagnosed glioblastoma patients from eight neurooncology specialized sites in Spain, they will use T10:C10, a THC and CBD extract from Tilray…

Continue Reading

MondayOct 23, 2023 12:46 pm

Five Ways to Treat Infectious Diseases While Keeping Antimicrobial Resistance in Check

Proper and early treatment is crucial to preventing worse patient outcomes and limiting community transmission when infectious diseases such as influenza, measles, hepatitis A, B, and C, and the novel coronavirus are involved. However, infectious-disease treatment can become less effective due to antimicrobial resistance (AMR), a phenomenon that occurs when fungi, viruses, parasites and bacteria stop responding to medications over time. This can make infectious diseases incredibly harder to treat with conventional treatment protocols because antimicrobial and antibiotic medicines become less effective, increasing the risk of severe illness and death. In the case of infectious diseases, antimicrobial resistance can make…

Continue Reading

MondayOct 23, 2023 9:45 am

Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Provides Insights on Definitive Agreement to Combine with GEDi Cube to Transform Medicine

Combined company brings together two innovative platforms in AI and biotherapeutics to offer comprehensive solutions spanning early cancer detection, diagnostic insights, and targeted immunotherapies The decision to join forces resulted from a carefully considered strategy to combine strengths and synergize work to elevate therapeutic efficacy and patient care By joining forces, the two technology divisions will collaborate to push new boundaries in precision diagnostics and targeted treatments GEDi Cube’s AI algorithms, trained using real-world data, could guide and accelerate Renovaro’s therapy development Renovaro’s intimate knowledge about vital aspects of the immune system and how cancers could respond to treatment may…

Continue Reading

MondayOct 23, 2023 9:00 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Promising Results in Its Pursuit of Safe, Effective Treatments for Large, Underserved Population of Plaque Psoriasis Patients

Scinai announced positive results suggesting the therapeutic potential of its anti-IL-17 VHH antibodies (NanoAbs) in treating plaque psoriasis The preclinical study showed that the introduction of the NanoAbs downregulated the standard molecular markers S100A7, CXCL1, and CCL20, that are often overexpressed in plaque psoriasis The study also revealed that the outer skin layers regained their normal appearance The company aims to provide safe, efficacious, specific, and more convenient treatment for the large and underserved population of mild to moderate plaque psoriasis patients Scinai is conducting an ex-vivo study to evaluate the anti-IL-17 NanoAbs in a full human skin model induced…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000